Entia Biosciences, Inc announced a private placement of series A convertible preferred stock for gross proceeds of $1,500,000 on November 13, 2013. The transaction was led by members of the company's board of directors and investment banker, who collectively purchased more than 25% of the total preferred stock. The transaction included participation from new investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% |
|
-.--% | -.--% |
2017 | Entia Biosciences, Inc. Announces Management Changes | CI |
2017 | Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3.41K | |
+17.72% | 44.87B | |
-10.33% | 37.8B | |
+42.27% | 37.61B | |
+29.36% | 31.32B | |
-8.44% | 27.4B | |
+12.45% | 26.32B | |
+44.19% | 14.07B | |
+31.93% | 12.5B | |
-7.67% | 11.23B |
- Stock Market
- Equities
- ERGO Stock
- News Entia Biosciences, Inc.
- Entia Biosciences, Inc. announced that it has received $1.5 million in funding